Brian T. Hill, MD, PhD, of the Cleveland Clinic, discusses study findings that showed consolidation with autologous hematopoietic cell transplant in the first remission improves overall survival in patients younger than age 65 (Abstract 341).
Joseph M. Connors, MD, of the British Columbia Cancer Agency, discusses study findings on a new front-line option: brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine in patients with previously untreated stage III or IV Hodgkin lymphoma (Abstract 6).
Michael Unterhalt, MD, of the University Hospital Grosshadern, discusses study findings on rituximab maintenance after first-line immunochemotherapy among older patients who are not candidates for autologous stem cell transplantation (Abstract 153).
Jakub Svoboda, MD, of the Abramson Cancer Center, University of Pennsylvania, discusses some encouraging phase I/II results on brentuximab vedotin with R-CHP chemotherapy as front-line treatment of CD30-positive primary mediastinal large B-cell, diffuse large B-cell, and gray zone lymphomas (Abstract 191).
Gilles A. Salles, MD, PhD, of the Université de Lyon, discusses study findings on rituximab maintenance after induction immunochemotherapy and the significant long-term progression-free survival benefit over observation (Abstract 486).
Andrew D. Zelenetz, MD, PhD, of Memorial Sloan Kettering Cancer Center, and Sattva S. Neelapu, MD, of The University of Texas MD Anderson Cancer Center, discuss long-term study findings on axicabtagene ciloleucel in patients with refractory aggressive non-Hodgkin lymphoma (Abstract 578).
